Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement
News|Articles|December 30, 2024

Our Top 5 Social Media Posts of 2024

Author(s)Miranda Schmalfuhs

Check out our top five most engaged social media posts from the year 2024.

Advertisement

1.

2.

3.

4.

5.

Advertisement

Related Content

Advertisement
Pharmaceutical Executive Daily

Pharmaceutical Executive Daily: FDA Approves Two Indications of Keytruda in Combination with Welireg

ByNicholas Jacobus
June 15th 2026
Stock.adobe.com fda approval

Pharma Roundup: FDA Approves Truqap Plus Abiraterone and Prednisone, FDA Approves Keytruda and Keytruda Qlex Each in Combination with Welireg

ByNicholas Jacobus
June 15th 2026
Sylvia Taylor

How Regulatory Shifts are Impacting the Vaccine Environment

ByMike Hollan,Silvia Taylor
June 15th 2026
Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim,

What Do You See as The Next Phase of Obesity Innovation?

ByNicholas Jacobus,Brian Hilberdink
June 15th 2026
Lisa Bollinger

Addressing Prohibitive Costs for Rare Diseases

ByMike Hollan,Lisa Bollinger
June 15th 2026
Advertisement
Advertisement

Trending on PharmExec

1

How Regulatory Shifts are Impacting the Vaccine Environment

2

Pharma Roundup: FDA Approves Truqap Plus Abiraterone and Prednisone, FDA Approves Keytruda and Keytruda Qlex Each in Combination with Welireg

3

What Do You See as The Next Phase of Obesity Innovation?

4

Addressing Prohibitive Costs for Rare Diseases

5

Kardigan Planning for $350 Million IPO Raise: Report

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us